Taking advantage of our expertise on mouse models and interactions with several clinical departments, our research focuses on the role of adaptive and innate immune cells in type 1 (T1D) and type 2 (T2D) diabetes/obesity and genetics of T1D. Our projects serve to understand disease mechanisms, discover biomarkers and develop therapeutic strategies.

The specific objectives are:
- Determine the role of innate type T lymphocytes in the regulation of T1D. NKT and MAIT cells are unconventional T cells that act as sensors of metabolic abnormalities. These innate-like T cells can regulate both innate and adaptive immunity. Our data demonstrated the efficiency of NKT and MAIT cells in preventing T1D.
- Determine the role of innate T lymphocytes in the regulation of T2D, obesity and non-alcoholic fatty liver disease. We have shown that in patients and mouse models, T2D and obesity induce alterations in MAIT cells, and high levels of inflammatory cytokines in adipose tissue. With our collaborators, we have shown that MAIT cells are profibrogenic in the liver of cirrhotic patients associated with non-alcoholic steatohepatitis (NASH).
- Develop "humanized" murine models that more closely mimic human T1D and understand the role of co-stimulation pathways in autoimmune activation against a given self-tissue. Such models are crucial for the initiation of clinical trials exploring vaccination strategies with cell antigens aimed at restoring immune tolerance.
- Determine the susceptibility to T1D and the genes and protective pathways involved in the diversity of juvenile diabetes, from multifactorial T1D to monogenic forms of diabetes whose clinical presentation may or may not be atypical.

Publications

Patents and networks

Methods and kits of assessing status, risk or prognosis of type 1 diabetes. WO 2017/162759, the 22nd March 2017 J. Da Silva, I. Nel, L. Beaudoin, A. Lehuen
Methods and pharmaceutical compositions for the treatment fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant (MAIT) cells. PCT/FR2017/0, the 22nd June 2017 P. Hegde, E. Weiss, V. Paradis, A. Lehuen, S. Lotersztajn
Methods for predicting whether a subject suffering from a cardiometabolic disease is at risk of progression toward heart failure. PCT/FR 17 306 257.1, the 25th September 2017 A. Lehuen, S. André, K. Clement
Methods for the diagnosis and treatment of type 1 diabetes. EP155250, February 19th 2015. S. Luce and C. Boitard

2019 - Label "Equipe FRM"
2018 - Award of the Fondation Francophone pour la Recherche sur le Diabète
2018 - Network on MAIT cells in type 1 diabetes (ANR Diab1MAIT)
2017 - Network Research Hospital-University in Health (RHU QUID NASH)

Funding

Contact